WallStSmart

Merck & Company Inc (MRK)vsOmada Health, Inc. Common Stock (OMDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 25175% more annual revenue ($65.77B vs $260.21M). MRK leads profitability with a 13.6% profit margin vs -4.9%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 3.3Quality: 4.8
Piotroski: 2/9

OMDA

Hold

37

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 6.7Quality: 5.8
Piotroski: 5/9Altman Z: -1.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-13.8%)

Margin of Safety

-13.8%

Fair Value

$97.84

Current Price

$111.38

$13.54 premium

UndervaluedFair: $97.84Overvalued
OMDAUndervalued (+41.8%)

Margin of Safety

+41.8%

Fair Value

$18.79

Current Price

$14.82

$3.97 discount

UndervaluedFair: $18.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$277.36B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

OMDA1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
58.1%10/10

Revenue surging 58.1% year-over-year

Areas to Watch

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

OMDA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$974.41M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
4.3%3/10

Operating margin of 4.3%

Return on EquityProfitability
-8.7%2/10

ROE of -8.7% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : OMDA

The strongest argument for OMDA centers on Revenue Growth. Revenue growth of 58.1% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Bear Case : OMDA

The primary concerns for OMDA are EPS Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

MRK profiles as a value stock while OMDA is a hypergrowth play — different risk/reward profiles.

OMDA is growing revenue faster at 58.1% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 37/100). OMDA offers better value entry with a 41.8% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Omada Health, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Omada Health, Inc. provides a range of virtual care programs in the United States. The company is headquartered in San Francisco, California.

Visit Website →

Want to dig deeper into these stocks?